Shattuck Labs

📍 Austin, United States🗓 Founded 2016👥 84 employees💰 Last funded Jul 2020
Biotechnology Research🌐 shattucklabs.com
Website LinkedIn
Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina.
2
Total investors
1
Early stage
1
Mid stage
0
Late stage
2016
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in Shattuck Labs?
Shattuck Labs has 2 investors on record on gritt.io, including 1 early-stage backers, 1 mid-stage.
When did Shattuck Labs last raise funding?
The most recent investment in Shattuck Labs recorded on gritt.io was in July 2020.
When was Shattuck Labs founded?
Shattuck Labs was founded in 2016.
What industry is Shattuck Labs in?
Shattuck Labs operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Shattuck Labs based?
Shattuck Labs is headquartered in Austin, United States.